hotspot -WSS

hotspot

author：hotspot 2025-09-04 05:34:38 - browse：3

illustration of one blue dna strand — Adobe

The Food and Drug Administration is convening a meeting of outside experts on Tuesday to review exa-cel, a CRISPR-based treatment for sickle cell disease made by Vertex Pharmaceuticals and CRISPR Therapeutics.

Tuesday’s meeting is set up a bit differently than most FDA advisory panels. The agency has not raised any concerns about exa-cel’s efficacy or safety, and there will not be a typical vote at the end of the day on whether the data from exa-cel’s pivotal clinical trial support an approval as a treatment for sickle cell disease.

Instead, the FDA is seeking input about the methods used by Vertex and CRISPR Therapeutics to evaluate the risk of inadvertently making unwanted changes to patients’ DNA — so-called off-target editing — when exa-cel is administered.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Resistance to opioid

leisure time

WSS

Roche subsidiary Foundation Medicine opens new headquarters

Congress must protect the remaining independent doctors

Scientists boost immune system in aging mice by making it youthful

Doctors on social media are being harassed and cyberbullied

Too many hospitalized Covid

Scientists boost immune system in aging mice by making it youthful

focus

hotspot

hotspot

How one medical school became remarkably diverse

Study gives hint on South Asians’ higher risk of cardiovascular disease

What does generative AI mean for health care? We asked experts

Merck drug for rare lung condition set for approval in U.S.

Peter Hotez and the public health issue of online harassment

Long Covid research funding gets a major boost from NIH

In age of alternative facts, a scholarly course on calling out crap

Too many hospitalized Covid

Continuity nursing helped my family in our darkest PICU moments

Study gives hint on South Asians’ higher risk of cardiovascular disease

hotspot

Steward Health Care has deal to sell doctor network to UnitedHealth

Vertex Pharmaceuticals may move headquarters in Boston

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Doctors on social media are being harassed and cyberbullied

leisure time

Wikipedia

leisure time

Wikipedia